Fuentes-Raspall Rafael, Puig-Vives Montserrat, Guerra-Prio Silvia, Perez-Bueno Ferran, Marcos-Gragera Rafael
Radiation Oncology Service, Catalan Institute of Oncology, Girona, Spain; Girona Biomedical Research Institute (IdiBGi), Girona, Spain.
Epidemiology Unit and Girona Cancer Registry (UERCG), Catalan Institute of Oncology, Girona, Spain; Girona Biomedical Research Institute (IdiBGi), Girona, Spain; Research Group on Statistics, Econometrics and Health (GRECS), Universitat de Girona, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Spain.
Cancer Epidemiol. 2014 Jun;38(3):244-7. doi: 10.1016/j.canep.2014.03.014. Epub 2014 Apr 29.
The present population-based study describes the survival of malignant central nervous system (CNS) tumors diagnosed during 15 years. Also, we obtained individual data regarding the use of temozolomide to analyze the impact of this drug on the survival of patients diagnosed with glioblastoma. From 1994 to 2008, a total of 679 incident cases of primary CNS tumors were reported by the Girona Cancer Registry after excluding 39 cases diagnosed by death certificate only. Number of cases and the corresponding proportion for each CNS histological subtype in the study population were: 25 oligodendroglial and oligoastrocytics (3.7%), 22 ependymal tumors (3.2%), 24 embryonal (3.5%), 372 astrocytic (54.8%), 1 choroid plexus (0.1%) and 235 without histological confirmation (34.6%). Observed survival after 5 years since diagnosis for the histological subtype were: 58.8%; 47.5%; 37.0%; 14.5% and 6.5%, respectively (p<0.001). Survival of patients diagnosed with glioblastoma according to temozolomide treatment (yes/no) was 60.8% vs. 13.6% and 5.9% vs. 2.5% after 1 and 5 years since diagnosis, respectively. Short-term survival was higher for patients diagnosed with glioblastoma and treated with temozolomide than patients not treated with temozolomide.
这项基于人群的研究描述了15年间诊断出的恶性中枢神经系统（CNS）肿瘤的生存情况。此外，我们获取了关于替莫唑胺使用的个体数据，以分析这种药物对胶质母细胞瘤患者生存情况的影响。1994年至2008年，吉罗纳癌症登记处共报告了679例原发性中枢神经系统肿瘤的发病病例，排除仅通过死亡证明诊断的39例后。研究人群中每种中枢神经系统组织学亚型的病例数及相应比例分别为：少突胶质细胞瘤和少突星形细胞瘤25例（3.7%），室管膜瘤22例（3.2%），胚胎性肿瘤24例（3.5%），星形细胞瘤372例（54.8%），脉络丛肿瘤1例（0.1%）以及235例未经组织学确诊（34.6%）。诊断后5年各组织学亚型的观察生存率分别为：58.8%；47.5%；37.0%；14.5%和6.5%（p<0.001）。诊断后1年和5年，根据是否接受替莫唑胺治疗，胶质母细胞瘤患者的生存率分别为60.8%对13.6%以及5.9%对2.5%。诊断为胶质母细胞瘤且接受替莫唑胺治疗的患者短期生存率高于未接受替莫唑胺治疗的患者。
